CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 152-160

  Wang, Cheng Yi ^a,b   Chao, Ting Ting ^a   Chang, Fang Yu ^a   Chen, Yen Lin ^a   Tsai, Yi Ting ^a   Lin, Hen I ^a   Huang, Yuh Chin T ^c   Shiau, Chung Wai ^d   Yu, Chong Jen ^e   Chen, Kuen Feng ^e  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; CIP2A; EGFR; Erlotinib; NSCLC; PP2A

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CASPASE 3; ERLOTINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROCASPASE 9; PROTEIN KINASE B; UNCLASSIFIED DRUG; AUTOANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; AUTOANTIGENS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84904103444     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.024     Document Type: Article

References (31)

1. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
2. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10:8195-8203.
6. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
7. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
8. Ciuleanu T., Stelmakh L., Cicenas S., Miliauskas S., Grigorescu A.C., Hillenbach C., et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13:300-308.
9. Junttila M.R., Puustinen P., Niemela M., Ahola R., Arnold H., Böttzauw T., et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62.
10. Soo Hoo L., Zhang J.Y., Chan E.K. Cloning and characterization of a novel 90kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002, 21:5006-5015.
11. Vaarala M.H., Vaisanen M.R., Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29:136.
12. Khanna A., Bockelman C., Hemmes A., Junttila M.R., Wiksten J.P., Lundin M., et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009, 101:793-805.
13. Katz J., Jakymiw A., Ducksworth M.K., Stewart C.M., Bhattacharyya I., Cha S., et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010, 10:694-699.
14. Dong Q.Z., Wang Y., Dong X.J., Li Z.X., Tang Z.P., Cui Q.Z., et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011, 18:857-865.
15. Ma L., Wen Z.S., Liu Z., Hu Z., Ma J., Chen X.Q., et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS ONE 2011, 6:e20159.
16. Xu P., Xu X.L., Huang Q., Hu Z., Ma J., Chen X.Q., et al. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol 2012, 29:1643-1647.
17. Come C., Laine A., Chanrion M., Edgren H., Mattila E., Liu X., et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009, 15:5092-5100.
18. Yu H.C., Chen H.J., Chang Y.L., Liu C.Y., Shiau C.W., Cheng A.L., et al. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 2013, 85:356-366.
19. Pallai R., Bhaskar A., Sodi V., Rice L.M. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 2012, 3:323-335.
20. Chen K.F., Pao K.C., Su J.C., Chou Y.C., Liu C.Y., Chen H.J., et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem 2012, 20:6144-6153.
21. Yu H.C., Hou D.R., Liu C.Y., Lin C.S., Shiau C.W., Cheng A.L., et al. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS ONE 2013, 8:e55705.
22. Liu C.Y., Shiau C.W., Kuo H.Y., Huang H.P., Chen M.H., Tzeng C.H., et al. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 2013, 98:729-738.
23. Lin Y.C., Wu M.H., Wei T.T., Chuang S.H., Chen K.F., Cheng A.L., et al. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia 2012, 14:463-475.
24. Tseng L.M., Liu C.Y., Chang K.C., Chu P.Y., Shiau C.W., Chen K.F. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012, 14:R68.
25. Lin Y.C., Chen K.C., Chen C.C., Cheng A.L., Chen K.F. CIP2A-mediated AKT activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 2012, 48:585-593.
26. Huang C.Y., Wei C.C., Chen K.C., Chen H.J., Cheng A.L., Chen K.F. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett 2012, 317:9-15.
27. Chen K.F., Yu H.C., Liu C.Y., Chen H.J., Chen Y.C., Hou D.R., et al. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther 2011, 10:892-901.
28. Chen K.F., Liu C.Y., Lin Y.C., Yu H.C., Liu T.H., Hou D.R., et al. CIP2A mediates effects of bortezomib on phospho-AKT and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29:6257-6266.
29. Sarris E.G., Saif M.W., Syrigos K.N. The biological role of PI3K pathway in lung cancer. Pharmaceuticals (Basel) 2012, 5:1236-1264.
30. Qiu Z.X., Zhang K., Qiu X.S., Zhou M., Li W.M. The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis. PLoS ONE 2013, 8:e81451.
31. Rikova K., Guo A., Zeng Q., Possemato A., Haack H., Yu J., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.